2021 Scientific Sessions
New Frontiers in Cardiovascular Research and Therapy

Rules and Guidelines for Abstract Submission

Submission deadline: June 2, 2021 at 6:00 PM Central Standard Time (CST)

To ensure that your abstract receives proper scientific consideration, be sure to submit to the appropriate category.

Abstract Submission:

The presenting author of an accepted abstract must pay the registration fee to attend BCVS 2021. Additional information about registration and fees will be available on the BCVS 2021 website in June.

All other expenses associated with the submission and presentation of an abstract are the responsibility of the presenter.

BCVS 2021 is a forum for the presentation of novel research findings. The work covered by the abstract must not have been published at the time of abstract submission or presented at a national meeting or world congress before August 23, 2021.

Exception: if early career investigators feel compelled to increase their opportunity of scientific interaction, then the abstract submission must have incremental information from the abstract presented elsewhere to justify submission and presentation at the AHA, should the investigator’s work be accepted at both meetings. Each investigator will determine, in good conscience, what constitutes incremental information and should notify AHA staff.

Submission of an abstract constitutes a commitment by the author(s) to present it if accepted. Failure to present, if not justified, will jeopardize future acceptance of abstracts for the American Heart Association.

There is no limit to the number of abstracts an investigator may submit. If selected, the presenter must be one of the co-authors listed.

Embargo Policy

Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA news event. Written embargoed information cannot be shared with anyone but one-on-one embargoed media interviews can be conducted as long as the reporter agrees to abide by the embargo policy. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. Click here to view the complete AHA/ASA General Embargo Policies.

Abstract Title

An abstract must have a short, specific title (containing no abbreviations) that indicates the nature of the investigation.

Author Name(s)

The submitting author is designated as the primary/presenting author. You may rearrange the order of the authors; however, always list the senior author last.
If an author’s name appears on more than one abstract, it must be identical on each abstract. Additions or deletions of author names are not permitted after June 2, 2021, 6:00 PM Central Time.

Abstract Data
Briefly describe the objectives of the study unless they are contained in the title. Include a brief statement of methods if pertinent. State findings in detail sufficient to support conclusions. Abstracts should not describe research in which the chemical identity or source of the reagent is proprietary or cannot be revealed.

Do not re-enter the abstract title or the authors’ names/institutions.

Use generic drug names.

Authors should not “split” data to create several abstracts from one. If splitting is judged to have occurred, priority scores of related abstracts will be reduced.

Standard abbreviations may be used without definition. Nonstandard abbreviations (kept to a minimum) must be placed in parentheses after the first use of the word or phrase abbreviated.

Do not include references, credits, or grant support.

Do not include names or personal information of any patient participating in the study or trial.

Abstracts are limited to 1,950 characters (about 300-350 words). This includes the text plus any graphic, but not the title or authors. Addition of a graphic will deduct 250 characters. Spaces do not count as characters.

Request oral or poster preferred presentation on the Presentation Preference page of the Abstract System. Selecting oral or poster preferred will neither prejudice acceptance nor guarantee oral or poster presentation, because abstracts must be arranged to fit into a thematic group for presentation. However, the AHA will make every effort to accommodate your presentation request.

If you select “Poster Only” and your abstract is accepted, this request will be granted.

Abstract Revisions
Proofread abstracts carefully to avoid errors. Abstracts may not be revised after June 2, 2021.

Abstract Withdrawal
Submit abstract withdrawal requests in writing by June 9, 2021.

Abstract Acceptance
Abstract grading is blinded, and abstracts are selected based on scientific merit and are allocated to oral or poster presentations.

Notification of abstract acceptance status will be emailed to presenting authors in late-June 2021. Please ensure that the email provided is accurate as all correspondences will be sent via email.

Accepted abstracts will be published in the online Circulation Research journal after the conference.

Abstract Presentation
Guidelines for presentations will be provided to authors of accepted abstracts.

All presentations and question-and-answer sessions will be conducted in English. Presenters may request assistance from the moderator, who will repeat or rephrase questions from the audience or may ask a colleague in the audience to assist with translation.
No person may record any portion of BCVS 2021, whether by video, still or digital photography; audio; or any other recording or reproduction mechanism. This includes recording of presentations and supporting audiovisual materials and of poster presentations and supporting poster materials.

Additionally, science information shared by investigators at the time of a meeting is confidential and often unpublished data. Taking photos of or recording the content of presentation slides is also prohibited and is considered intellectual piracy and unethical. Attendees who ignore this policy will be asked to leave the educational session and are at risk of losing their badge credentials.

The AHA reserves the right to all video or audio recordings of presentations at BCVS 2021.

**Abstracts Copyright Transfer Agreement**

During the abstract submission process, you will have the opportunity to provide your approval (electronically) of the copyright transfer agreement. Your approval of this agreement indicates:

- The author(s) hereby assigns, conveys, and otherwise transfers all rights, title, interest, and copyright ownership in said work to the AHA/ASA effective upon acceptance of said work for presentation. “Work” includes the material submitted for presentation and any other related material submitted to the AHA/ASA.
- The assignment of rights, title, interest, and copyright ownership in the Work to the AHA includes, but is not expressly limited to, rights to edit, publish, reproduce, distribute copies, prepare derivative works, include in indexes or search databases in print, electronic, on the Internet, or in any other media, whether or not created or in use at the time of execution of this agreement, and claim copyright in said work throughout the world for the full duration of the copyright and any renewals or extensions thereof. If this is a jointly created Work, all co-authors correspondingly assign all rights, title, and interest in said Work to the AHA by the execution of this Agreement.
- In the event that the AHA does not present or publish said Work, Author(s) will be so notified, and all rights assigned hereunder will revert to the Author(s).

*The assignment of rights hereunder does not extend to the full-length article on which the abstract is based.*

- Author(s) retain the right to subsequently include the work in articles, books, or derivative works that he/she authors, or edits provided said use does not imply the endorsement of the AHA/ASA.
- Other uses or reproductions require permission from the AHA/ASA, which shall not be unreasonably withheld.
- Author(s) hereby represents and warrants that he/she/they is/are sole author(s) of the work, that all authors have participated in and agree with the content and conclusions of the work, and that the work is original and does not infringe upon any copyright, proprietary, or personal right of any third party.
- If the AHA/ASA does not publish said work, author(s) will be notified, and all rights assigned hereunder will revert to author(s).
- If a joint work, all co-authors must transfer rights in said work to the AHA/ASA by executing this Agreement.
- This Agreement must be executed as is without revision or substitution of terms. A handwritten signature of the author(s) is required.
- This Agreement is governed by the laws of the United States of America.

- **For U.S. Government Employee Author(s):**
  The author(s) hereby warrants that the above-described work was authored by employees of the United States government as part of their official duties and therefore may be published and reproduced without restriction.